Compare iShares MSCI Germany (DAX) (EWG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares MSCI Germany (DAX) trades at $41.98 (market cap $1.44B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 89× iShares MSCI Germany (DAX)'s market cap, and Vertex Pharmaceuticals Incorporated is more actively traded (806,603 versus 1,258,794). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 56 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| EWG | VRTX | |
|---|---|---|
Market Cap | $1.44B | $128.16B |
Volume | 1,258,794 | 806,603 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $557.96 |
52-Week Low | $38.08 | $407.37 |
Typical Hold Time | 56 Days | 120 Days |
Enterprise Value | — | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG is trading at $40.91, down 1.4% today amid bearish technical signals with 19 sell indicators versus 1 buy. The stock faces resistance at $41 with support at $40, while European market sentiment remains cautious due to ECB rate hike expectations and energy price pressures. Key financial ratios are unavailable in the current dataset.
The outlook remains cautious with technical indicators signaling bearish momentum and European macroeconomic headwinds from potential ECB tightening. Investment opportunities depend on resolution of energy inflation concerns, while risks include further rate hikes and deteriorating eurozone business confidence.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
